Acquisition of multiple copies of a mutant topoisomerase IIα allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines

J. A. Campain, M. L. Slovak, Patricia V Schoenlein, N. C. Popescu, M. M. Gottesman, I. Pastan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Mutants of the human melanoma cell line, FEM-X, selected in multiple steps with VP-16 (etoposide), are cross resistant to the epipodophyllotoxins and doxorubicin. Complementary DNA's for topoisomerase IIα were cloned from both FEM-X and FVP3, the most resistant mutant. Deletion of nucleotides 1320-1322 (or Ala429 from the resulting topoisomerase IIα protein) was unique to the cDNA from the drug resistant cell line. Expression of the mutant mRNA increases in parallel with VP-16 resistance in this series of cell lines. Restriction analysis and Southern analysis with allele-specific oligonucleotide probes were used to quantify the ratio of wild-type to mutant topoisomerase IIα alleles present in DNA amplified by PCR from both FEM-X and the drug resistant sublines. This analysis shows that in cell lines of increasing drug resistance, the number of mutant topoisomerase IIα alleles increases incrementally along with a concomitant decrease in the number of wild-type alleles. By quantitative Southern analysis of genomic DNA the total number of topoosomerase IIα alleles in FVP3 is approximately 2-fold that in the parental cells. Fluorescence in situ hybridization with a chromosome 17 paint reveals that amplification of the topoisomerase IIα locus in FVP3 correlates with an increase in the number of chromosome 17's, specifically the long arm. Cytogenetic analysis demonstrates that FEM-X contains three copies of chromosome 17, two of which are morphologically normal. During drug selection, FVP3 has gained 2-3 additional copies of the long arm of chromosome 17, the chromosomal location of the topoisomerase IIα locus. In this subline it is likely that three copies of the topoisomerase IIα gene are found on normal chromosome 17's and two on an isochromosome of the long arm of 17. By pulsed field gel electrophoresis, we were able to detect changes in the restriction pattern of the region of the long arm of chromosome 17 around the topoisomerase IIα locus that correlate with observed cytogenetic changes in FVP3. These results suggest that the acquisition of the mutant allele of topoisomerase IIα confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIα mRNA over that of the wild-type which is associated with a concomitant increase in the number of mutant topoisomerase IIα alleles.

Original languageEnglish (US)
Pages (from-to)451-471
Number of pages21
JournalSomatic Cell and Molecular Genetics
Volume21
Issue number6
DOIs
StatePublished - Nov 1 1995

Fingerprint

Type II DNA Topoisomerase
Chromosomes, Human, Pair 17
Aneuploidy
Etoposide
Melanoma
Alleles
Cell Line
Pharmaceutical Preparations
Complementary DNA
Isochromosomes
Podophyllotoxin
Messenger RNA
Paint
Oligonucleotide Probes
Cytogenetic Analysis
Pulsed Field Gel Electrophoresis
DNA
Fluorescence In Situ Hybridization
Drug Resistance
Cytogenetics

ASJC Scopus subject areas

  • Genetics
  • Cell Biology

Cite this

Acquisition of multiple copies of a mutant topoisomerase IIα allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. / Campain, J. A.; Slovak, M. L.; Schoenlein, Patricia V; Popescu, N. C.; Gottesman, M. M.; Pastan, I.

In: Somatic Cell and Molecular Genetics, Vol. 21, No. 6, 01.11.1995, p. 451-471.

Research output: Contribution to journalArticle

@article{31d042ed936f4ca18941dbc02f87d13e,
title = "Acquisition of multiple copies of a mutant topoisomerase IIα allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines",
abstract = "Mutants of the human melanoma cell line, FEM-X, selected in multiple steps with VP-16 (etoposide), are cross resistant to the epipodophyllotoxins and doxorubicin. Complementary DNA's for topoisomerase IIα were cloned from both FEM-X and FVP3, the most resistant mutant. Deletion of nucleotides 1320-1322 (or Ala429 from the resulting topoisomerase IIα protein) was unique to the cDNA from the drug resistant cell line. Expression of the mutant mRNA increases in parallel with VP-16 resistance in this series of cell lines. Restriction analysis and Southern analysis with allele-specific oligonucleotide probes were used to quantify the ratio of wild-type to mutant topoisomerase IIα alleles present in DNA amplified by PCR from both FEM-X and the drug resistant sublines. This analysis shows that in cell lines of increasing drug resistance, the number of mutant topoisomerase IIα alleles increases incrementally along with a concomitant decrease in the number of wild-type alleles. By quantitative Southern analysis of genomic DNA the total number of topoosomerase IIα alleles in FVP3 is approximately 2-fold that in the parental cells. Fluorescence in situ hybridization with a chromosome 17 paint reveals that amplification of the topoisomerase IIα locus in FVP3 correlates with an increase in the number of chromosome 17's, specifically the long arm. Cytogenetic analysis demonstrates that FEM-X contains three copies of chromosome 17, two of which are morphologically normal. During drug selection, FVP3 has gained 2-3 additional copies of the long arm of chromosome 17, the chromosomal location of the topoisomerase IIα locus. In this subline it is likely that three copies of the topoisomerase IIα gene are found on normal chromosome 17's and two on an isochromosome of the long arm of 17. By pulsed field gel electrophoresis, we were able to detect changes in the restriction pattern of the region of the long arm of chromosome 17 around the topoisomerase IIα locus that correlate with observed cytogenetic changes in FVP3. These results suggest that the acquisition of the mutant allele of topoisomerase IIα confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIα mRNA over that of the wild-type which is associated with a concomitant increase in the number of mutant topoisomerase IIα alleles.",
author = "Campain, {J. A.} and Slovak, {M. L.} and Schoenlein, {Patricia V} and Popescu, {N. C.} and Gottesman, {M. M.} and I. Pastan",
year = "1995",
month = "11",
day = "1",
doi = "10.1007/BF02310211",
language = "English (US)",
volume = "21",
pages = "451--471",
journal = "Somatic Cell and Molecular Genetics",
issn = "0740-7750",
publisher = "Springer GmbH & Co, Auslieferungs-Gesellschaf",
number = "6",

}

TY - JOUR

T1 - Acquisition of multiple copies of a mutant topoisomerase IIα allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines

AU - Campain, J. A.

AU - Slovak, M. L.

AU - Schoenlein, Patricia V

AU - Popescu, N. C.

AU - Gottesman, M. M.

AU - Pastan, I.

PY - 1995/11/1

Y1 - 1995/11/1

N2 - Mutants of the human melanoma cell line, FEM-X, selected in multiple steps with VP-16 (etoposide), are cross resistant to the epipodophyllotoxins and doxorubicin. Complementary DNA's for topoisomerase IIα were cloned from both FEM-X and FVP3, the most resistant mutant. Deletion of nucleotides 1320-1322 (or Ala429 from the resulting topoisomerase IIα protein) was unique to the cDNA from the drug resistant cell line. Expression of the mutant mRNA increases in parallel with VP-16 resistance in this series of cell lines. Restriction analysis and Southern analysis with allele-specific oligonucleotide probes were used to quantify the ratio of wild-type to mutant topoisomerase IIα alleles present in DNA amplified by PCR from both FEM-X and the drug resistant sublines. This analysis shows that in cell lines of increasing drug resistance, the number of mutant topoisomerase IIα alleles increases incrementally along with a concomitant decrease in the number of wild-type alleles. By quantitative Southern analysis of genomic DNA the total number of topoosomerase IIα alleles in FVP3 is approximately 2-fold that in the parental cells. Fluorescence in situ hybridization with a chromosome 17 paint reveals that amplification of the topoisomerase IIα locus in FVP3 correlates with an increase in the number of chromosome 17's, specifically the long arm. Cytogenetic analysis demonstrates that FEM-X contains three copies of chromosome 17, two of which are morphologically normal. During drug selection, FVP3 has gained 2-3 additional copies of the long arm of chromosome 17, the chromosomal location of the topoisomerase IIα locus. In this subline it is likely that three copies of the topoisomerase IIα gene are found on normal chromosome 17's and two on an isochromosome of the long arm of 17. By pulsed field gel electrophoresis, we were able to detect changes in the restriction pattern of the region of the long arm of chromosome 17 around the topoisomerase IIα locus that correlate with observed cytogenetic changes in FVP3. These results suggest that the acquisition of the mutant allele of topoisomerase IIα confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIα mRNA over that of the wild-type which is associated with a concomitant increase in the number of mutant topoisomerase IIα alleles.

AB - Mutants of the human melanoma cell line, FEM-X, selected in multiple steps with VP-16 (etoposide), are cross resistant to the epipodophyllotoxins and doxorubicin. Complementary DNA's for topoisomerase IIα were cloned from both FEM-X and FVP3, the most resistant mutant. Deletion of nucleotides 1320-1322 (or Ala429 from the resulting topoisomerase IIα protein) was unique to the cDNA from the drug resistant cell line. Expression of the mutant mRNA increases in parallel with VP-16 resistance in this series of cell lines. Restriction analysis and Southern analysis with allele-specific oligonucleotide probes were used to quantify the ratio of wild-type to mutant topoisomerase IIα alleles present in DNA amplified by PCR from both FEM-X and the drug resistant sublines. This analysis shows that in cell lines of increasing drug resistance, the number of mutant topoisomerase IIα alleles increases incrementally along with a concomitant decrease in the number of wild-type alleles. By quantitative Southern analysis of genomic DNA the total number of topoosomerase IIα alleles in FVP3 is approximately 2-fold that in the parental cells. Fluorescence in situ hybridization with a chromosome 17 paint reveals that amplification of the topoisomerase IIα locus in FVP3 correlates with an increase in the number of chromosome 17's, specifically the long arm. Cytogenetic analysis demonstrates that FEM-X contains three copies of chromosome 17, two of which are morphologically normal. During drug selection, FVP3 has gained 2-3 additional copies of the long arm of chromosome 17, the chromosomal location of the topoisomerase IIα locus. In this subline it is likely that three copies of the topoisomerase IIα gene are found on normal chromosome 17's and two on an isochromosome of the long arm of 17. By pulsed field gel electrophoresis, we were able to detect changes in the restriction pattern of the region of the long arm of chromosome 17 around the topoisomerase IIα locus that correlate with observed cytogenetic changes in FVP3. These results suggest that the acquisition of the mutant allele of topoisomerase IIα confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIα mRNA over that of the wild-type which is associated with a concomitant increase in the number of mutant topoisomerase IIα alleles.

UR - http://www.scopus.com/inward/record.url?scp=0029553541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029553541&partnerID=8YFLogxK

U2 - 10.1007/BF02310211

DO - 10.1007/BF02310211

M3 - Article

VL - 21

SP - 451

EP - 471

JO - Somatic Cell and Molecular Genetics

JF - Somatic Cell and Molecular Genetics

SN - 0740-7750

IS - 6

ER -